About RayzeBio, Inc. Common Stock (RYZB) β Dividend Analysis 2026
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The companyβs lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
Is RYZB a good dividend investment in 2026?
RYZB offers a 3.20% forward yield with a 50% payout ratio. Strand Safety Score: 0/100 (Critical Risk). The 5-year dividend CAGR of 0% is modest β investors should weigh current income against growth alternatives.
RYZB DRIP calculator β what's the difference?
With DRIP on a $10,000 investment over 10 years, your RYZB portfolio grows to $13.7K vs $13.2K without reinvestment. This is the compound interest effect in action.
RYZB dividend growth history & forecast
RYZB has grown its dividend by 0% over the last year and 0% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 3.20%.
Company generates negative FCF ($-61M) β borrowing to pay dividends
Debt Leverage0.0Γ Debt/EBITDA
0 / 30 pts
0/30
Company not generating EBITDA β debt servicing risk is elevated
Earnings Momentum-0.1B β -0.0B β -0.0B
0 / 30 pts
0/30
Company is reporting net losses β dividend sustainability is in question
OVERALL ASSESSMENT
High risk of dividend cut β weak fundamentals across multiple factors.
STRAND SCORE
0
/100
Strand Safety Scoreβ’ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
π RYZB Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold RYZB.
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
π― RYZB Income Goal & Break-Even
Dividend Break-Even
37yr
Years for dividends to fully repay your RYZB investment of $62.49/share (πΊπΈ US Taxable (15%) Β· 15.00% tax)
$10K invested Β· 10 Years
Dividends earned (DRIP)
$3.1K
Lost to inflation (2.8% CPI)
β$2.5K
Real purchasing power gain
$606.52
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in RYZB for:
Shares needed
14,118
Capital required
$882,234
Monthly income
$2,000
Based on current dividend of $2.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
π RYZB Dividend Payment Schedule
RYZB pays quarterly β 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
π°
Apr
May
Jun
π°
Jul
Aug
Sep
π°
Oct
Nov
Dec
π°
10 shares
$4.25 / payment
$17.00 / year after tax
100 shares
$42.50 / payment
$170.00 / year after tax
1,000 shares
$425.00 / payment
$1700.00 / year after tax
π RYZB vs Healthcare Benchmarks
How RYZB compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yieldβ²+0.40% vs sectorBetter
RYZB
3.20%
avg
2.80%
5Y Dividend CAGRβΌ-6.80% vs sectorBelow avg
RYZB
0.00%
avg
6.80%
Payout Ratioβ²-5.00% vs sectorBetter
RYZB
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for RYZB sourced from FMP /financial-growth endpoint β real data, not estimates.
ποΈ RYZB Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
Insider
Title
Type
Date
Shares
Price
Total Value
VIKING GLOBAL INVESTORS LP
10 percent owner
J-Other
2024-02-26
1,743,556
$62.50
$108.97M
Redmile Group, LLC
10 percent owner
C-Conversion
2023-09-19
498,510
β
β
Redmile Group, LLC
10 percent owner
C-Conversion
2023-09-19
494,687
β
β
Redmile Group, LLC
10 percent owner
C-Conversion
2023-09-19
864,509
β
β
Redmile Group, LLC
10 percent owner
C-Conversion
2023-09-19
432,254
β
β
Redmile Group, LLC
10 percent owner
C-Conversion
2023-09-19
498,510
β
β
Redmile Group, LLC
10 percent owner
C-Conversion
2023-09-19
864,509
β
β
venBio Global Strategic Fund III, L.P.
10 percent owner
C-Conversion
2023-09-19
247,343
β
β
venBio Global Strategic Fund III, L.P.
10 percent owner
C-Conversion
2023-09-19
1,123,862
β
β
venBio Global Strategic Fund III, L.P.
10 percent owner
C-Conversion
2023-09-19
3,786,957
β
β
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
π About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the RYZB dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β